SI-BONE, Inc. (NASDAQ:SIBN – Get Free Report) shares were down 6.4% on Monday . The stock traded as low as $15.12 and last traded at $15.13. Approximately 152,554 shares changed hands during mid-day trading, a decline of 62% from the average daily volume of 402,689 shares. The stock had previously closed at $16.16.
Analyst Ratings Changes
Several equities analysts have recently weighed in on SIBN shares. Morgan Stanley dropped their price objective on shares of SI-BONE from $25.00 to $21.00 and set an “overweight” rating on the stock in a research report on Monday, July 15th. JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of SI-BONE in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $27.00 price objective on shares of SI-BONE in a research report on Tuesday, May 7th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.67.
SI-BONE Trading Down 6.4 %
The firm has a market capitalization of $623.43 million, a P/E ratio of -13.89 and a beta of 1.20. The business’s 50-day moving average is $13.92 and its 200 day moving average is $16.12. The company has a debt-to-equity ratio of 0.22, a current ratio of 9.76 and a quick ratio of 8.75.
SI-BONE (NASDAQ:SIBN – Get Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. SI-BONE had a negative net margin of 29.93% and a negative return on equity of 25.14%. The business had revenue of $37.87 million for the quarter, compared to analyst estimates of $36.45 million. As a group, analysts anticipate that SI-BONE, Inc. will post -0.95 EPS for the current fiscal year.
Insiders Place Their Bets
In other SI-BONE news, CFO Anshul Maheshwari sold 2,441 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.14, for a total transaction of $36,956.74. Following the sale, the chief financial officer now directly owns 204,241 shares in the company, valued at $3,092,208.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other SI-BONE news, CFO Anshul Maheshwari sold 2,441 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.14, for a total transaction of $36,956.74. Following the sale, the chief financial officer now directly owns 204,241 shares in the company, valued at $3,092,208.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Anthony J. Recupero sold 3,309 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $12.92, for a total transaction of $42,752.28. Following the completion of the sale, the insider now owns 243,629 shares in the company, valued at $3,147,686.68. The disclosure for this sale can be found here. Insiders have sold 11,956 shares of company stock worth $172,555 over the last ninety days. Corporate insiders own 5.40% of the company’s stock.
Institutional Investors Weigh In On SI-BONE
Hedge funds have recently made changes to their positions in the stock. Amalgamated Bank boosted its stake in shares of SI-BONE by 12.9% in the 4th quarter. Amalgamated Bank now owns 5,877 shares of the company’s stock valued at $123,000 after purchasing an additional 673 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after purchasing an additional 2,108 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of SI-BONE in the 2nd quarter valued at approximately $152,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in SI-BONE by 14.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,541 shares of the company’s stock worth $179,000 after buying an additional 1,106 shares during the period. Finally, RiverPark Advisors LLC boosted its position in SI-BONE by 260.4% during the 1st quarter. RiverPark Advisors LLC now owns 11,357 shares of the company’s stock worth $186,000 after buying an additional 8,206 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.
About SI-BONE
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.